1. Home
  2. NUS vs TENX Comparison

NUS vs TENX Comparison

Compare NUS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nu Skin Enterprises Inc.

NUS

Nu Skin Enterprises Inc.

HOLD

Current Price

$4.83

Market Cap

266.5M

Sector

Health Care

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.83

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUS
TENX
Founded
1984
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
266.5M
317.8M
IPO Year
1996
2001

Fundamental Metrics

Financial Performance
Metric
NUS
TENX
Price
$4.83
$1.83
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
538.1K
6.2M
Earning Date
05-07-2026
05-15-2026
Dividend Yield
3.36%
N/A
EPS Growth
207.80
N/A
EPS
N/A
N/A
Revenue
$3,176,718,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.98
N/A
52 Week Low
$4.49
$1.31
52 Week High
$14.62
$19.40

Technical Indicators

Market Signals
Indicator
NUS
TENX
Relative Strength Index (RSI) 38.87 18.20
Support Level N/A N/A
Resistance Level $5.51 $16.39
Average True Range (ATR) 0.23 0.88
MACD -0.04 -1.52
Stochastic Oscillator 33.66 3.42

Price Performance

Historical Comparison
NUS
TENX

About NUS Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: